Substance Use Disorder

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

A patient loss does not undo or discard the multitude of meaningful life changing and life preserving work done.

Revisiting the CME articles featured in Psychiatric Times in 2022.

While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.

What are the most pertinent drug trends to be aware of in 2023?

We may be one step closer to nonprescription naloxone.

In this CME article, explore the mental health consequences associated with the COVID-19 pandemic as well as the potential role for complementary and alternative approaches.

What is recovery?

From traumatic brain injury to the dangers of excessive social media usage, here are highlights from the week in Psychiatric Times.

Comorbid SUD and ADHD is associated with more severe illness. What do we understand about these comorbid conditions and what do we still need to learn?

Fentanyl is now available in ways it was not before, which may lead to fatal outcomes.

Opioid use, addiction, and overdose in youth continue to increase. What can be done?

The experts weighed in on a wide variety of psychiatric issues for the September 2022 issue of Psychiatric Times.

The NCCHC and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.

Contingency management is an effective behavior change technique commonly used to treat substance use disorders.

Suicide Prevention Week is September 4-10. Are you ready?

New data shows a decrease in life expectancy in the United States. Here’s why.

The experts weighed in on a wide variety of psychiatric issues for the August 2022 issue of Psychiatric Times.

“Doctors are great at hiding their addictions, especially from themselves... However, there are signs that something is wrong—be it addiction, depression, psychosis, or some other problem.”

Opioid use disorder—how can we battle the epidemic of overdoses?

Medication, counseling, and support—just as important in substance use disorder treatment as any other brain disease.

Cannabis use disorder and nonadherence: How can we best educate patients?

Positive results from the phase 3 trial of AD04 show a 79% reduction in heavy drinking.